Search Results
Baxter Announces $100 Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility
Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced an approximately $100 million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany.
Our Most Vulnerable Kidney Patients During COVID-19
Ken Sutha, M.D., Ph.D., is a pediatric nephrologist at Stanford Children's Health, Palo Alto, Calif. As a kidney patient and a physician, he understands the challenges COVID-19 presents.
Baxter Highlights New Data Indicating Sharesource Digital Health Platform for Home Dialysis May Improve Survival and Reduce Hospitalizations
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data showing kidney patients may experience a survival rate nearly two-times higher and a prolonged time to an adverse event (AE) and hospitalization when the Sharesource remote patient management digital health platform is used to help manage home automated peritoneal dialysis (APD).1
Filling a Critical Role in Pharmaceutical Drug Development and Manufacturing
When in need of specialized development services and/or large-scale production, pharmaceutical companies often turn to contract development and manufacturing organizations like Baxter BioPharma Solutions (BPS), who are equipped to support them with scientific expertise and manufacturing capacity for products such as COVID-19 vaccines.
Baxter to Present at Evercore ISI 4th Annual HealthCONx Conference
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 4th Annual HealthCONx Conference on Thursday, December 2, 2021. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 9:40 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through May 21, 2022.
Baxter Reports Third-Quarter 2021 Results
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2021.
Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury
Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. The NEPHROCLEAR™ CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways.
Brainstorming for Business Solutions
Flexibility and a sense of ownership create a work environment at Baxter that drives the best possible results in our mission to save and sustain lives. With leadership support, our entrepreneurial ideas become reality.
Unlocking a Life of Possibilities with Home Parenteral Nutrition
For 19-year-old Nutrition and Food Science student Trinity, home parenteral nutrition provides the opportunity to live an unencumbered life.